share_log

Predictive Oncology to Report First Quarter 2024 Financial Results On Wednesday, May 15, 2024

Predictive Oncology to Report First Quarter 2024 Financial Results On Wednesday, May 15, 2024

预测肿瘤学将于2024年5月15日星期三公布2024年第一季度财务业绩
Predictive Oncology ·  05/10 00:00

Management to host conference call and webcast at 8:30am ET

管理层将在美国东部时间上午 8:30 主持电话会议和网络直播

PITTSBURGH, May 10, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the first quarter ended March 31, 2024 before the markets open on Wednesday, May 15, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET.

匹兹堡,2024年5月10日(GLOBE NEWSWIRE)——Predictive Oncology Inc.(纳斯达克股票代码:POAI)是一家以科学为导向的公司,利用其专有的人工智能和机器学习能力、庞大的肿瘤样本生物库、临床实验室改进修正案(CLIA)实验室和良好生产规范(GMP)设施,以加快肿瘤药物的发现并促进药物开发。该公司今天宣布,将在2024年3月31日之前公布截至2024年3月31日的第一季度财务业绩市场将于2024年5月15日星期三开盘。该公司将在美国东部时间上午 8:30 举办公司更新电话会议和网络直播音频。

Live Conference Call & Webcast:
Toll Free: 877-407-3982
International: 201-493-6780
Conference ID: 13746389
Call me: here
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1669074&tp_key=149e847466
电话会议直播和网络直播:
免费电话: 877-407-3982
国际: 201-493-6780
会议编号: 13746389
给我打电话: 这里
网络直播: https://viavid.webcasts.com/starthere.jsp?ei=1669074&tp_key=149e847466


A replay of the webcast will be available in the Investors section of the Predictive Oncology website at https://investors.predictive-oncology.com/events-and-presentations.


网络直播的重播将在预测肿瘤学网站的 “投资者” 栏目中播出,网址为 https://investors.predictive-oncology.com/events-and-presentations

About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company's scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the Company's vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry's broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. Predictive Oncology is headquartered in Pittsburgh, PA.

关于预测肿瘤学
Predictive Oncology 在人工智能和机器学习的使用迅速增长方面处于前沿,以加快早期药物发现并实现药物开发,造福全球癌症患者。该公司经过科学验证的人工智能平台PEDAL能够以92%的准确率预测肿瘤样本是否会对某种药物化合物产生反应,从而可以更明智地选择药物/肿瘤类型的组合进行后续体外测试。Predictive Oncology 再加上公司庞大的生物库,里面有超过 150,000 个具有检测能力的异源人类肿瘤样本,为其学术和行业合作伙伴提供了业内最广泛的人工智能药物发现解决方案之一,其全资拥有的 CLIA 实验室和 GMP 设施进一步补充了这一点。预测肿瘤学总部位于宾夕法尼亚州匹兹堡。

Contact:
Predictive Oncology Inc.
Theresa Ferguson, Senior Director of Marketing
Phone: (630) 566-2003
tferguson@predictive-oncology.com

联系人:
预测肿瘤学公司
特蕾莎·弗格森,营销高级董事
电话:(630) 566-2003
tferguson@predictive-oncology.com

Predictive Oncology Investor Relations
Tim McCarthy
LifeSci Advisors, LLC.
tim@lifesciadvisors.com

预测肿瘤学投资者关系
蒂姆·麦卡锡
LifeSci Advisors, LLC
tim@lifesciadvisors.com

Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "would," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading "Risk Factors" in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

前瞻性陈述:
本新闻稿中讨论的某些事项包含前瞻性陈述。这些前瞻性陈述反映了我们当前对未来事件的预期和预测,并受有关我们的运营和投资的重大风险、不确定性和假设的影响。本新闻稿中有关我们的战略、未来运营、未来财务状况、未来收入和财务业绩、预计成本、前景、管理层变动、管理计划和目标的所有陈述,除历史事实陈述外,均为前瞻性陈述。“预期”、“相信”、“估计”、“期望”、“打算”、“可能”、“计划”、“将”、“目标” 等词语以及类似的表述旨在识别前瞻性陈述,尽管并非所有前瞻性陈述都包含这些识别词。由于多种因素,包括我们在向美国证券交易委员会提交的文件中 “风险因素” 标题下讨论的因素等,我们的实际未来表现可能与前瞻性陈述所设想的存在重大差异。除非法律明确要求,否则公司不承担任何更新这些前瞻性陈述的意图或义务。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发